FROM THE EDITOR
My October 22 article ended with a tease about Liquidia launching YUTREPIA into the PAH and PH-ILD markets at risk, losing the Hatch-Waxman trial, and facing an injunction motion. I told you the at-risk launch was the GC’s most concentrated legal exposure.
In this article I talk about how the exposure was resolved. On September 30, the Delaware court upheld two of United Therapeutics’ ‘327 patent claims — the ones Liquidia had conceded it infringed. Liquidia’s stock fell approximately 57 percent in a single session. Thirteen days later, on October 13, the parties filed an 8-K and announced a global settlement.
This article is about what happens after you lose.
The Liquidia settlement is a GC primer on a sequence that the Hatch-Waxman litigation calendar produces regularly but that rarely gets examined as a legal document: adverse judgment, rapid negotiation, settlement agreement that does what the court order would not quite do, and a disclosure sequence that puts 13 days between a market-moving event and its resolution. The legal work in those 13 days is the article.
One note on sourcing: the $380.7M figure in this article comes from Liquidia’s accounting in the 8-K filing. The 8-K itself does not state that total; it reports each payment obligation separately. The merger of those obligations into a single number requires arithmetic across the document, which I have done and which should be confirmed against the full settlement agreement when it is filed.
John LaRocca
THE LITIGATION CONTEXT
Liquidia launched YUTREPIA (treprostinil) inhalation powder into the pulmonary arterial hypertension (PAH) market in January 2024, and into the pulmonary hypertension associated with interstitial lung disease (PH-ILD) market shortly after. The launch was at risk — meaning Liquidia filed its NDA under the 505(b)(2) pathway and began commercial sales before patent litigation with United Therapeutics was resolved.
At-risk launch is the most aggressive posture available to a drug company in Hatch-Waxman litigation. It means you have concluded, on advice of counsel and after analysis of the litigation record, that the probability-weighted value of early market entry exceeds the probability-weighted cost of an adverse judgment plus injunction. That calculation requires legal analysis of both the merits (how strong are the remaining asserted patents?) and the remedy question (is an injunction automatic, or does equity review apply?).
For Liquidia, the calculus appeared favorable when the launch decision was made. By September 30, 2026, two patent claims on the ‘327 patent had been upheld in Delaware — claims that Liquidia had conceded it infringed. The concession meant the litigation was never about whether YUTREPIA infringed those claims. It was about whether those claims were valid. The court concluded they were.
With validity established and infringement conceded, the exposure calculus changed entirely. What remained was the injunction motion — and United Therapeutics was seeking one.
WHAT THE SETTLEMENT DOES
The global settlement filed October 13 resolves every pending dispute between the parties, including the ‘327 patent litigation, disputes with distributors and PBM counterparties, and related third-party claims. It does not read like a simple patent license. It reads like a business arrangement designed to allocate the litigation’s commercial consequences among all the parties who held a piece of the exposure.
The payment structure, as reported in the 8-K:
$175.0 million to United Therapeutics, net, within 30 business days of the settlement date
$145.4 million more to United Therapeutics in two installments through April 30, 2027
$21.75 million from Sandoz (a distributor counterparty) into escrow
$19.05 million from Henderson (an additional related party) into escrow
$19.45 million from PBM counterparties into escrow
The aggregate, computing across all obligations, is approximately $380.7 million in total consideration flowing from the Liquidia ecosystem to United Therapeutics and related parties. For Liquidia itself, the direct payment obligation is $320.4 million — a number that must be understood against the company’s cash position and lender covenants, addressed below.
The indication carve-out:
Liquidia agreed to file with FDA to remove the PH-ILD indication from the YUTREPIA label. YUTREPIA will continue to be marketed for PAH. The PH-ILD commercial program ends.
This is a structural distinction that deserves attention. United Therapeutics did not obtain, through the settlement, a court injunction barring YUTREPIA’s sale. What it obtained was a contractual commitment — enforceable between the parties — that Liquidia will seek FDA approval of a label change that removes the contested indication from the product’s approved uses. The settlement closes a chapter of YUTREPIA’s commercial history not through a court order but through a regulatory filing.
The conditioned releases:
The mutual releases in the settlement do not take effect at signing. They are conditioned on FDA’s approval of the label amendment removing PH-ILD from the YUTREPIA label. Until FDA acts, the parties’ legal claims remain technically live.
THE FDA-CONDITIONED RELEASE — WHY THIS MATTERS
Patent settlement agreements are regularly structured to include conditions — regulatory approvals, milestone events, antitrust clearances — that must occur before the agreement becomes fully effective. But using FDA label approval as the triggering condition for mutual releases is a specific choice that deserves unpacking.
The conventional structure for an indication carve-out in patent litigation is an injunction or a consent decree: the court orders the defendant to stop commercializing the product for the infringing indication, and that order is self-executing. The settlement structure here is different. Liquidia is not under a court order. Liquidia has made a contract. The contract says Liquidia will file for the label change. The label change will happen only after FDA acts — which could take months.
From United Therapeutics’ perspective, the conditioned release structure protects against a scenario in which Liquidia commits to a label change but FDA delays or declines to process it on the expected timeline. If FDA does not approve the label change, the release does not take effect, and UTHR retains its legal claims. The settlement is, in this sense, contingent on a regulatory outcome that neither party fully controls.
From Liquidia’s perspective, the conditioned release creates a period of legal limbo: the company has agreed to the settlement, paid or committed to pay the consideration, committed to stop promoting YUTREPIA for PH-ILD, and is waiting for FDA to process the label amendment before its claims against UTHR are formally released. During that period, YUTREPIA remains approved for both indications, but Liquidia has committed contractually not to promote one of them.
For GCs who handle settlement negotiations, the FDA-conditioned release model is worth understanding as a tool. It allows the parties to reach commercial finality on behavior (stop promoting) before obtaining legal finality on releases (FDA action), which is often the sequence that makes a deal possible when regulatory timing is uncertain.
THE LENDER CONSENT AND COVENANT RESET
One provision in the settlement that does not appear in typical patent litigation summaries: HCR Collateral Management, Liquidia’s lender, was a party to — or at minimum a necessary counterparty to — the settlement. As a condition of the settlement, HCR raised Liquidia’s minimum cash covenant from $15 million to $45 million.
This is a significant restructuring of the credit agreement concurrent with the settlement. To understand why it matters: a minimum cash covenant is the floor below which the borrower’s cash balance cannot fall without triggering a covenant default. At $15 million, Liquidia had a relatively thin covenant cushion. At $45 million, the lender has tripled the floor — meaning Liquidia must maintain three times the pre-settlement minimum cash balance at all times while the credit agreement is outstanding.
The lender reset serves two functions. First, it protects HCR against the risk that Liquidia’s cash position deteriorates as the settlement payments flow out over the next six months — the $320.4 million in direct Liquidia obligations will reduce cash materially, and the lender wanted a higher minimum balance as a buffer against further deterioration. Second, it signals to the capital markets that the lender remains comfortable with the credit, has reviewed the settlement, and has agreed to remain in place at a restructured covenant level.
For GCs involved in any litigation that generates a significant cash payment obligation, the interaction between the settlement and the credit agreement is a parallel legal track that must run concurrently with settlement negotiation. A settlement that the lender will not consent to is not a settlement. A settlement that the lender consents to only on terms that impose new constraints on the borrower changes the company’s financial flexibility from the moment it closes.
BOX: THE AT-RISK LAUNCH DECISION — WHAT THE GC NEEDS BEFORE THE PRODUCT SHIPS
The Liquidia settlement illustrates the endpoint of an at-risk launch that goes badly. The GC’s work is to ensure the company understood the risk profile before the product shipped — and that the company is positioned to manage the consequence.
Five things the GC needs to have in place before a Hatch-Waxman at-risk launch:
1. A litigation risk assessment that models the adverse case. Not just “we think we’ll win.” A specific analysis of what the judgment looks like if the asserted claims are upheld, what the injunction standard is in the relevant jurisdiction, and what the full commercial damage exposure is (lost profits to the patentee, reasonable royalty, potentially treble damages if the launch is found willful).
2. A lender analysis. Does the credit agreement contemplate an adverse judgment of this magnitude? Is a covenant default triggered by a judgment, an injunction, or just a cash payment? The lender needs to be in the conversation before the product ships, not after the court rules.
3. A remediation plan for the adverse case. What does the settlement look like if you lose? Who are the counterparties who need to be at the table (distributors, PBMs, third-party rebate administrators)? What contractual infrastructure needs to be in place so that a settlement negotiation can move in days, not weeks, when the judgment comes down?
4. A disclosure framework. The adverse judgment is a material event. The 8-K must go out promptly. The settlement, if reached quickly, is a second material event. The legal team needs to have the disclosure framework ready — the drafts, the review chain, the board communication — so that disclosure is not delayed while the settlement is being negotiated.
5. An indication carve-out plan. If the product has multiple indications, what does a partial resolution look like? An indication carve-out — as Liquidia executed through a label amendment commitment — is a settlement tool that may be unavailable if it was not anticipated in the commercial infrastructure. How are the revenue streams for each indication tracked separately? Can the company market to one indication cleanly after the settlement?
THE DISCLOSURE SEQUENCE
The September 30 judgment and the October 13 settlement are both material events. The gap between them — 13 calendar days — is where Reg FD and Exchange Act Section 13 disclosure obligations intersect with the practical reality of settlement negotiation.
Liquidia disclosed the September 30 adverse judgment in a Form 8-K filed promptly after the decision. The stock fell approximately 57 percent. That disclosure was straightforward: a material adverse litigation outcome, promptly disclosed, with a clear market impact.
The October 13 settlement 8-K is the more legally interesting document. It discloses: (a) the resolution of the litigation, (b) the payment structure and aggregate obligation, (c) the indication carve-out and label amendment commitment, and (d) the lender covenant reset. Each of those items is material. Each was available as a disclosure item only after the settlement agreement was signed — because until then, they were pending negotiations that fell within the attorney-client privilege and the protection of settlement discussions.
The 13-day window is not a disclosure failure. It is the negotiation period. A company that has suffered an adverse judgment faces pressure to settle as quickly as possible, because an injunction motion remains live and the lender’s patience is not unlimited. The GC’s task during those 13 days is to close the settlement — with all its counterparties, including distributors and PBM parties who had their own exposure — fast enough that the injunction is not pursued and the company is not in default.
For public company GCs, the Liquidia sequence is a model of how patent litigation and disclosure obligations interact in compressed time. The lesson is not that 13 days is too long. The lesson is that the 13-day window has to be used to finish a complex, multi-party agreement — and the GC who has not pre-built the counterparty relationships and document infrastructure before the adverse judgment arrives is negotiating under deadline pressure with no leverage and a stock that has already moved.
WHAT THE GC ON EACH SIDE NEEDED TO GET RIGHT
Liquidia (defendant) side:
The task was to convert a litigation loss into a business outcome: preserve the PAH business, eliminate the injunction risk on the PH-ILD business, pay the settlement over a timeline that the lender will accept, and close the releases against a settlement counter-party who had just won in court and had limited incentive to be generous.
Structurally, the GC needed to get four things done simultaneously: negotiate the payment terms with UTHR; coordinate the escrow obligations with Sandoz, Henderson, and the PBM counterparties; obtain lender consent and negotiate the covenant reset; and manage the disclosure obligations to the capital markets at each stage. Those are four parallel tracks that all had to close within 13 days.
The indication carve-out — preserving PAH while surrendering PH-ILD — was likely the key commercial value capture from the settlement. YUTREPIA’s PAH market position, which is not covered by the ‘327 patent claims that were upheld, is preserved. The company exits the settlement as a commercial business, not a company under injunction.
United Therapeutics (plaintiff) side:
UTHR had won. The question was whether winning in court would produce more value than a settlement. An injunction, if granted, would have cleared YUTREPIA from the PH-ILD market immediately — but injunctions in pharmaceutical patent cases are not automatic under eBay Inc. v. MercExchange, and litigation to enforce the injunction adds cost and timeline. A settlement that achieves the same commercial result — YUTREPIA out of PH-ILD — while generating $175 million upfront and $145.4 million more over six months, avoids the injunction enforcement risk and generates certain cash consideration.
The conditioned release was UTHR’s tool for ensuring the label change actually happens. Until FDA acts, UTHR retains its legal claims. The settlement is, from UTHR’s perspective, a deal that generates more certain value than an injunction proceeding — and conditions finality on the regulatory outcome that was the commercial point of the case.
WORKSTREAM 1 — IMMEDIATE: Build Your At-Risk Launch Legal Infrastructure Before the Product Ships
The Liquidia settlement is the outcome of an at-risk launch plan that did not survive contact with an adverse judgment on a patented indication. Before the next at-risk launch in your portfolio, the legal team needs a documented framework that answers five questions:
What is the specific adverse-case analysis, including injunction standard and commercial damage exposure? What is the lender’s position if the adverse case materializes? Who are the third-party counterparties whose cooperation a rapid settlement will require? What does the disclosure framework look like for both the judgment and the settlement? And — most importantly — what is the indication carve-out plan if the product has multiple indications and only one is contested?
Those five questions are not asked enough during at-risk launch planning, because the launch decision is a commercial and litigation risk assessment, and the commercial team wins the argument. The GC’s job is to ensure that if the launch goes badly, the company has a path to resolution that preserves the business.
BUSINESS IMPACT: The 13-day negotiation window between an adverse judgment and a settlement is only achievable if the infrastructure was built before the product shipped. A GC who builds the framework is positioned to close the settlement. A GC who is building the framework after the stock has fallen 57 percent is behind the timeline.
WORKSTREAM 2 — NEAR-TERM: Model the Lender Interaction in Any Litigation-Adjacent Transaction
The HCR covenant reset is a reminder that the company’s lenders are never passive observers in material litigation. Lenders read 8-Ks. They model cash flows against covenant floors. They are forming a view about whether to consent, exercise remedies, or renegotiate terms well before they take any visible action.
Map the lender’s covenants against any adverse litigation scenario before the scenario materializes. Know, in advance, which covenants are triggered by a judgment versus a cash payment, what the notice and cure periods are, and who at the lender relationship is the right counterparty for an early conversation about a developing litigation risk.
The companies that negotiate lender covenant resets on favorable terms are the ones whose GC had the conversation with the lender relationship manager before the 8-K was filed, not after. The lender who reads about the adverse judgment in the financial press and receives a consent request in the same week is a lender operating from a defensive posture. The lender who has been in the conversation is a partner.
BUSINESS IMPACT: A covenant default triggered by a litigation judgment is a separate legal crisis layered on top of the litigation itself. The GC who manages the lender relationship proactively converts that crisis into a negotiation. The GC who does not manage it converts it into a default waiver process that consumes legal resources and management bandwidth at the worst possible moment.
WORKSTREAM 3 — STRATEGIC: Understand the Multi-Party Settlement Architecture in Hatch-Waxman Litigation
The Liquidia settlement involves not just Liquidia and United Therapeutics but also Sandoz, Henderson, and PBM counterparties — each contributing to escrow as part of the global resolution. That architecture reflects a reality that at-risk launch analyses often underweight: when a drug launches at risk through a commercial distribution network, every party in that network has litigation exposure.
Distributors who shipped the product may face conversion claims. PBMs who processed claims for the infringing indication have their own exposure under theories that range from aiding and abetting to direct participation. Third parties who manufactured, distributed, or facilitated the commercial program are not bystanders to the patent case — they are counterparties whose consent and contribution a global settlement will require.
The GC who has mapped those relationships and understood the legal theory of each party’s exposure before the launch is in a position to structure a settlement that closes all the exposure in a single agreement. The GC who discovers those relationships after the adverse judgment is managing a much more complex negotiation.
BUSINESS IMPACT: A global settlement that closes all exposure is worth more than a bilateral settlement that leaves distributor and PBM claims live. Building the commercial and legal infrastructure to achieve a global settlement requires understanding, before launch, who the relevant parties are and what their exposure is.
“The 13-day window between an adverse judgment and a settlement is only achievable if the infrastructure was built before the product shipped. The GC who builds the framework is positioned to close the settlement.”
ABOUT THE AUTHOR
John LaRocca is the founder of LaRocca Advisory Services and the author of The GC Playbook. He served as CLO at Aerie Pharmaceuticals (Aerie/Alcon, ~$930M), Y-mAbs Therapeutics (SERB, $412M), and Eagle Pharmaceuticals, with 37 years of legal experience and 26 years at the GC/CLO level in specialty pharma and biotech. The GC Playbook is published on Substack at laroccaj.substack.com.


